Global Masiroxavir Tablets Market Strategic Research Report

Scope of the Report

The global Masiroxavir Tablets market size is predicted to grow from US$ 110 million in 2025 to US$ 854 million in 2032; it is expected to grow at a CAGR of 37.3% from 2026 to 2032.

Baloxavir Marboxil Tablets is a new, oral, single-dose anti-influenza virus drug belonging to cap-dependent endonuclease inhibitors. It exerts its effect by inhibiting influenza virus gene replication, which can rapidly eliminate the virus, shorten the course of disease, and reduce infectivity. Clinically, it is mainly used for the treatment of influenza A and B in people aged 12 years and older. It features rapid onset, convenient administration, and good tolerability, and is currently a first-line targeted anti-influenza drug in clinical practice.In 2025, global production of Baloxavir Marboxil Tablets reached approximately 120 million tablets

As a new-generation anti-influenza drug, Baloxavir Marboxil Tablets (Xofluza) has rapidly become an important player in the global anti-influenza market relying on its core advantages of single oral dose, rapid onset and high compliance. Its unique cap-dependent endonuclease inhibition mechanism can block virus proliferation at the early stage of replication and significantly shorten the course of disease and infectious period. In the Chinese market, the drug has achieved rapid growth since its approval in 2021, and its accessibility has been significantly improved through medical insurance access, occupying a mainstream position in the high-end anti-influenza segment. With the successive launch of domestic generic drugs and innovative drugs, market competition has intensified, and the market will present a tripartite pattern of imported original drugs, domestic generic drugs and domestic innovative drugs in the future. Meanwhile, drug resistance risk and medical insurance cost control will become key factors affecting its long-term market development.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Masiroxavir Tablets market?

What factors are driving Masiroxavir Tablets market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Masiroxavir Tablets market opportunities vary by end market size?

How does Masiroxavir Tablets break out by Type, by Application?

This report presents a comprehensive overview of the global Masiroxavir Tablets market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 20 mg per tablet
• 40 mg per tablet

Segment by Target Population

• Patients Aged 12 Years And Older With Influenza A
• Patients Aged 12 Years And Older With Influenza B

Segment by Sales Channels

• Hospital
• Retail
• Online

Segment by Production Technology

• Innovator
• Generic

Segment by Application

• Influenza A
• Influenza B
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Masiroxavir Tablets market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Influenza A, Influenza B, Others evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact